Isomorphic Labs President Jaderberg: All future drugs will be designed by AI
Max Jaderberg, President of AI drug discovery company Isomorphic Labs, predicts that all future drugs will be designed by AI, though the timeline remains uncertain, and he does not want to passively wait 20 or even 50 years. Isomorphic Labs was spun out of Google DeepMind and has raised approximately $2.7 billion in cumulative funding; it is currently in talks for a new funding round that could value the company at $40 billion or more. The company plans to launch its first clinical trials before the end of the year and is currently still in the preclinical testing stage.
Body · AI translation
Isomorphic Labs President Judenberg boldly predicts: all future drugs will be designed by AI. IT Home Download the app for exclusive early access. November 03, 2026, 11:28:04, from Shandong. Updated November 03, 2026, 11:50:09
IT Home, November 3 news: According to Bloomberg, Max Judenberg, President of the artificial intelligence pharmaceutical company Isomorphic Labs, believes that all drugs in the future will be designed by AI, and the only difference is how long it will take to achieve this goal. "That day will definitely come. I have no doubt that all drugs in the future will be designed by AI. I just don't want everyone to wait passively, only for it to take 20 or even 50 years to happen."
On the 2nd local time, at the Bloomberg Tech Summit held in London, Judenberg introduced that the lab hopes to use AI to improve the speed and efficiency of new drug development. It is still in the preclinical trial stage, and the company's development has only just begun.
In January this year, Demis Hassabis, CEO of Isomorphic Labs, revealed that the company planned to launch its first clinical trials before the end of the year.
Isomorphic Labs was spun off from Google DeepMind under Alphabet. In addition to using AI models to independently develop drugs, it also provides drug development technology to biopharmaceutical companies such as Eli Lilly and Novartis.
Isomorphic Labs has raised approximately US$2.7 billion in total (IT Home note: at the current exchange rate, about RMB 17.997 billion), with investors including Alphabet and Thrive Capital. The company is recently negotiating a new round of financing, with its valuation expected to reach US$40 billion (at the current exchange rate, about RMB 266.616 billion) or more. When the previous financing round was announced in May this year, Isomorphic Labs did not disclose the company's valuation.
Isomorphic Labs was founded in 2021 and led by Hassabis, who was then CEO of Google DeepMind, hoping to build on the breakthrough achieved by the protein structure prediction model AlphaFold to further advance drug development. In August this year, Hassabis moved to the role of Chairman of Google DeepMind and Chief Scientist of Alphabet, while continuing to serve as CEO of Isomorphic Labs.
The drugs independently developed by Isomorphic Labs are mainly used to treat cancer, immune system diseases, and inflammation.
Judenberg believes that new drug development in the past relied heavily on repeated trial and error, and what was found was mostly relatively easy gains. "I think humans are actually not very good at developing drugs. It is simply a miracle that we have so many excellent drugs."
"Special statement: The above content (including videos, pictures, and audio if any) is uploaded and published by users of 'Dafeng Hao,' a self-media platform under Phoenix Net. This platform only provides information storage space services.
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services."